Cisplatin Resistance: Genetic and Epigenetic Factors Involved

Author(s)

Lugones, Yuliannis ; Loren, Pia ; Salazar, Luis A.

• Document type: Journal article
• Source: BIOMOLECULES; v. 12, n. 10, p. 12-pg., 2022-10-01.

Abstract

Cisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor cells can acquire resistance to the damage caused by cisplatin, generating genetic and epigenetic changes that lead to the generation of resistance and the activation of intrinsic resistance mechanisms in cancer cells. Among them, we can find mutations, alternative splicing, epigenetic-driven expression changes, and even post-translational modifications of proteins. However, the molecular mechanisms by which CDDP resistance develops are not clear but are believed to be multi-factorial. This article highlights a description of cisplatin, which includes action mechanism, resistance, and epigenetic factors involved in cisplatin resistance. (AU)

• FAPESP's process: 19/13250-1 - Cisplatin-induced nephrotoxicity: contribution of clinical, genetic and epigenetic factors
• Grantee: Patricia Moriel
• Support Opportunities: Regular Research Grants